[Barsha’s Story #4] “With each relapse, I ask myself if I am an unfit mother? I don’t want pity. I want to be able to make breakfast. If there is a treatment that will allow me to continue driving my sons to school, I want to know about it. I have spent hours online researching different treatment options. I want to speak with my neurologist about switching to PRODUCT X.” Only PRODUCT X has been proven to deliver near-complete suppression of subclinical (MRI) activity with superior clinical outcomes versus high-dose IFN β-1a in two identical 2-year trials. Across both trials, PRODUCT X… Demonstrated near-complete suppression of T1 Gd+ lesions Reduced relapse rates by nearly half and the risk of disability progression by 40% Barsha wants to make the switch to higher-efficacy PRODUCT X today and halt progression. But, before you act… PRODUCT X has demonstrated a favourable safety profile that allows for earlier intervene in the course of disease. In fact, across two identical 2-year trials… No cases of opportunistic infections were reported The most common adverse drug reaction was infusion-related reactions; mostly mild to moderate, the incidence was highest during the first dose and decreased over time Now, you can suppress subclinical activity and halt further disease progression with the assurance of favourable safety. To treat earlier with higher-efficacy, start PRODUCT X now.
Issuu converts static files into: digital portfolios, online yearbooks, online catalogs, digital photo albums and more. Sign up and create your flipbook.